Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) Equity Average: 2019-2025

Historic Equity Average for Kymera Therapeutics (KYMR) over the last 6 years, with Sep 2025 value amounting to $958.9 million.

  • Kymera Therapeutics' Equity Average rose 21.54% to $958.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $958.9 million, marking a year-over-year increase of 21.54%. This contributed to the annual value of $615.3 million for FY2024, which is 39.03% up from last year.
  • Latest data reveals that Kymera Therapeutics reported Equity Average of $958.9 million as of Q3 2025, which was up 9.10% from $878.9 million recorded in Q2 2025.
  • Kymera Therapeutics' 5-year Equity Average high stood at $958.9 million for Q3 2025, and its period low was $266.7 million during Q2 2021.
  • Moreover, its 3-year median value for Equity Average was $698.1 million (2024), whereas its average is $662.6 million.
  • Per our database at Business Quant, Kymera Therapeutics' Equity Average skyrocketed by 432.40% in 2021 and then fell by 21.19% in 2023.
  • Kymera Therapeutics' Equity Average (Quarterly) stood at $471.4 million in 2021, then increased by 6.39% to $501.5 million in 2022, then fell by 21.19% to $395.3 million in 2023, then skyrocketed by 118.66% to $864.3 million in 2024, then increased by 21.54% to $958.9 million in 2025.
  • Its Equity Average was $958.9 million in Q3 2025, compared to $878.9 million in Q2 2025 and $810.9 million in Q1 2025.